wondering why pps still falling- isit bc of ZN's tweet that

New Post Public Reply Private Reply Replies (0) Message Board
microcaps microcaps #23
280
wondering why pps still falling- isit bc of ZN's tweet that no info on well testing will be revealed till the testing is done? which asper the May 17 PR of 7-10 das for basic testing/zone would be ca 50 days from beginning of testing

the rights exercised last couple days of may -cannot convert warrant whatever til june29 for 3/share

the options and warrants on this stock can be hard to keep track of as the following from the 10q indicates
so many options available at 1c-when exercised many such shares-once vested -are sold into the market reducing pps

in the 3 options immediately below the table below would imply most options granted to senior officers were already exercised by mar 31,but items in i and iii could result in pps dilution june 30 ff

A. 2011 Equity Incentive Stock Option Plan



During the three months ended March 31, 2018, the Company granted the following options from the 2011 Equity Incentive Plan for employees, directors and consultants, to purchase as non-cash compensation (the exercise of penny stock options are taxable on the date of exercise):


i. Options to purchase 330,000 shares of Common Stock to 23 senior officers, staff members and consultants at an exercise price of $.01 per share. The options have vesting schedules of 165,000 shares on June 30, 2018 and 165,000 shares on December 31, 2018. The options are exercisable through January 1, 2028. The fair value of the options at the date of grant amounted to approximately $759,000.

ii. Options to purchase 110,000 shares of Common Stock to five senior officers at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2028. The fair value of the options at the date of grant amounted to approximately $250,000.

iii. Options to purchase 55,000 shares of Common Stock to three consultants an exercise price of $0.01 per share. The options vested upon grant. However, the exercisability of these options is according to the following schedule: (a) 27,500 options are exercisable on June 30, 2018 and (b) the remaining 27,500 options are exercisable on June 30, 2019. The fair value of the options at the date of grant amounted to $222,000.



B. 2011 Non-Employee Directors Stock Option Plan



During the three months ended March 31, 2018, the Company granted the following qualified (market value) options from the 2011 Non-Employee Directors Stock Option Plan for directors to purchase as non-cash compensation:


i. Options to purchase 400,000 shares of Common Stock to eight board members at an exercise price of $2.31 per share. The options vested upon grant and are exercisable through January 1, 2024. The fair value of the options at the date of grant amounted to approximately $428,000.


9





Zion Oil & Gas, Inc.



Notes to Financial Statements



Note 3 - Stockholders’ Equity (cont’d)



C. Stock Options



The stock option transactions since January 1, 2018 are shown in the table below:




Number of

shares


Weighted Average

exercise price

US$
Outstanding, December 31, 2017 4,339,443 1.37

Changes during 2018 to:
Granted to employees, officers, directors and others * 895,000 1.04
Expired/Cancelled/Forfeited - -
Exercised (4,500 ) 0.01
Outstanding, March 31, 2018 5,229,943 1.31
Exercisable, March 31, 2018 4,824,943 1.42



* The receipt of a stock option grant by the grantee recipient is a non-taxable event according to the Internal Revenue Service. The grantee who later chooses to exercise penny stock options must recognize the market value in income in the year of exercise.



The following table summarizes information about stock options outstanding as of March 31, 2018:



Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested)
Range of
exercise
price Number outstanding Weighted average remaining contractual life (years) Weighted
Average
Exercise
price Range of exercise
price Number
Outstanding Weighted average remaining contractual life (years) Weighted
Average
Exercise
price
US$ US$ US$ US$
— — — — 0.01 15,000 5.62 0.01
— — — — 0.01 15,000 6.00 0.01
— — — — 0.01 5,000 6.20 0.01
— — — — 0.01 15,000 7.35 0.01
— — — — 0.01 10,000 7.50 0.01
— — — — 0.01 25,000 7.75 0.01
— — — — 0.01 355,000 8.18 0.01
— — — — 0.01 575,000 8.75 0.01
— — — — 0.01 10,000 8.76 0.01
— — — — 0.01 80,000 9.04 0.01
— — — — 0.01 10,000 9.42 0.01
0.01 20,000 9.50 0.01 0.01 20,000 9.50 0.01
0.01 295,000 9.75 0.01 0.01 *35,000 9.75 0.01
— — — — 0.01 **55,000 9.91 0 .01
— — — — 0.01 110,000 9.76 0.01
— — — — 1.33 25,000 5.08 1.38
— — — — 1.38 108,000 2.76 1.38
— — — — 1.38 123,057 6.76 1.38
— — — — 1.55 400,000 4.18 1.38
— — — — 1.67 390,000 2.50 1.67
— — — — 1.67 458,886 6.51 1.67
— — — — 1.70 120,000 0.73 1.70
— — — — 1.70 298,500 4.73 1.70
— — — — 1.73 25,000 0.78 1.73
— — — — 1.75 400,000 5.27 1.70
— — — — 1.86 25,000 0.68 1.86
— — — — 1.87 25,000 3.84 1.87
— — — — 1.95 25,000 2.00 1.95
— — — — 1.96 25,000 1.43 1.96
— — — — 2.03 25,000 3.08 2.03
— — — — 2.28 25,000 1.27 2.28
— — — — 2.31 400,000 5.76 2.31
— — — — 2.61 681,500 3.68 2.61
0.01 315,000 0.01 0.01-2.61 4,914,943 1.40



*17,500 options are exercisable on June 30, 2018 and 17,500 are exercisable on December 31, 2018.

**27,500 options are exercisable on June 30, 2018 and 27,500 are exercisable on June 30, 2019.

10





Zion Oil & Gas, Inc.



Notes to Financial Statements



Note 3 - Stockholders’ Equity (cont’d)



Granted to employees



The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:


For the three months ended
March 31,
2018 2017
Weighted-average fair value of underlying stock at grant date $ 2.31 $ 1.37
Dividend yields — —
Expected volatility 68%-70 % 60 %
Risk-free interest rates 2.01%-2.25 % 1.86%-1.93 %
Expected lives (in years) 3.50-5.50 5.00
Weighted-average grant date fair value $ 1.69 $ 1.36



Granted to non-employees



The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:


For the three months ended
March 31,
2018 2017
Weighted-average fair value of underlying stock at grant date $ 3.37 $ 1.36
Dividend yields — —
Expected volatility 73%-76 % 68 %
Risk-free interest rates 2.46%-2.81 % 2.36%-2.45 %
Expected lives (in years) 10.00 10.00
Weighted-average grant date fair value $ 3.36 $ 1.36


11





Zion Oil & Gas, Inc.



Notes to Financial Statements



Note 3 - Stockholders’ Equity (cont’d)



The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options.



The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life.



D. Compensation Cost for Warrant and Option Issuances



The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors:


For the three months ended March 31,
2018 2017
US$ thousands US$ thousands
943 2,015



The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees:


For the three months ended March 31,
2018 2017
US$ thousands US$ thousands
302 210



The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties:


For the three months ended March 31,
2018 2017
US$ thousands US$ thousands
297 191



As of March 31, 2018, there was approximately $465,000 of unrecognized compensation cost, related to non-vested stock options granted under the Company’s various stock option plans. The cost is expected to be recognized during the years 2018 and 2019.



E. Dividend Reinvestment and Stock Purchase Plan (“DSPP”)



On March 27, 2014, the Company launched its Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended.



12





On January 13, 2015, the Company amended the Original Prospectus Supplement (“Amendment No. 3”) to provide for a unit option (the “Unit Option”) under the DSPP comprised of one share of Common Stock and three Common Stock purchase warrants with each unit priced at $4.00. Each warrant afforded the participant the opportunity to purchase the Company’s Common Stock at a warrant exercise price of $1.00. Each of the three warrants series has different expiration dates that have been extended.



The warrants became exercisable on May 2, 2016 and, in the case of ZNWAB continued to be exercisable through May 2, 2017 (1 year) and, in the case of ZNWAC continued to be exercisable through May 2, 2018 for ZNWAC (2 years) and May 2, 2019 for ZNWAD (3 years), respectively, at a per share exercise price of $1.00.



As of May 2, 2017, any outstanding ZNWAB warrants expired.



As of May 2, 2018, any outstanding ZNWAC warrants expired.



On November 1, 2016, the Company launched a unit offering (the “Unit Program”) under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10.



The warrant has the symbol “ZNWAE.”



The ZNWAE warrants became exercisable on May 1, 2017 and continue to be exercisable through May 1, 2020 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination the warrant upon providing 60 days advanced notice to the warrant holders.



On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.



On May 22, 2017, the Company launched a new unit offering (the “New Unit Program”). The New Unit Program consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The New Unit Program terminated on July 12, 2017. This New Unit Program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share.



The warrant has the symbol “ZNWAF.”



All ZNWAF warrants became exercisable on August 14, 2017 and continue to be exercisable through August 14, 2020 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.



On October 16, 2017, the Company initiated another Unit Option Program which terminated on December 6, 2017. This Unit Option Program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share.



13





The warrant has the symbol “ZNWAG.”



The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2021 at a per share exercise price of $1.00. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.



On February 1, 2018, the Company’s latest Unit Option began and terminated on February 28, 2018. The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00.



The warrant has the symbol “ZNWAH.”



The warrants became exercisable on April 2, 2018 and continue to be exercisable through April 2, 2019 at a per share exercise price of $5.00.



For the three months ended March 31, 2018, approximately $3,835,000 was raised under the DSPP program.



The warrants represented by the ticker ZNWAA are tradable on the NASDAQ market. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.



The warrant transactions since January 1, 2018 are shown in the table below:


ZNWAA ZNWAC ZNWAD ZNWAE ZNWAF ZNWAG ZNWAH Total
Outstanding warrants, December 31, 2017 1,524,617 275,152 294,334 3,028,119 460,231 414,300 - 5,996,753
Exercise Price $ 2.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 1.00 $ 5.00
Warrant Termination Date 1/31/2020 5/2/2018 5/2/2019 5/2/2020 8/14/2020 1/8/2021 4/2/2019
Change during 2018 to:
Issued - - - 10,493 50 30 373,650 384,223
Exercised (12,825 ) (76,015 ) (6,194 ) (408,346 ) (51,585 ) (159,385 ) - (714,350 )
Expired - - - - - - - -
Outstanding warrants, March 31, 2018 1,511,792 199,137 288,140 2,630,266 408,696 254,945 373,650 5,666,626



14





Zion Oil & Gas, Inc.



Notes to Financial Statements



Note 3 - Stockholders’ Equity (cont’d)



E. Warrant Descriptions



The price and the expiration dates for the series of warrants to investors are as follows:


Period of Grant US$ Expiration Date

ZNWAA Warrants March 2013 – December 2014 2.00 January 31, 2020
ZNWAC Warrants January 2015 – March 2016 1.00 May 02, 2018
ZNWAD Warrants January 2015 – March 2016 1.00 May 02, 2019
ZNWAE Warrants November 2016 – March 2017 1.00 May 01, 2020
ZNWAF Warrants May 2017 – July 2017 1.00 August 14, 2020
ZNWAG Warrants October 2017 – December 2017 1.00 January 08, 2021
ZNWAH Warrants February 2018 5.00 April 2, 2019



15



Zion Oil & Gas, Inc. (ZNOG) Stock Research Links

ZNOG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Updated Category News Views 62

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Continue Reading
Jill De Forest Honored: A Journey Through Recruitment

Updated Category News Views 74

A Force in Recruitment: Jill De Forest There's a name that reverberates through the corridors of executive search and recruitment: Jill De Forest. Recognized by The Inner Circle as the Pinnacle Professional of The Year, De Forest has left a profound mark on the industry with her knack for matching exceptional talent to major brands. Trailblazing through Executive Search...

Continue Reading
Longevity Tour Hits East Coast: Brecka's Mission

Updated Category News Views 135

Bringing Longevity to the East Coast This weekend, something interesting is happening on the East Coast of the U.S. Gary Brecka and his Ultimate Longevity Center (ULC) are holding a series of events in Philadelphia, New York, and Boston. Everything kicks off on November 14th. If the idea of 'live longevity' leaves you scratching your head, don’t worry—I've got you...

Continue Reading
Solar Cooking Revolution: InventHelp's Latest Innovation

Updated Category News Views 56

A Bright Idea Shines with Solar Cooking Some days, you stumble across an idea that just seems destined to shake things up, and COOK SOL SOLAR POWER COOKER might just be one of those spark plugs ready to ignite the world of outdoor cooking. Invented by a plucky thinker from Florence, South Carolina, this little gadget isn't just about frying up eggs on a camping trip. Nah,...

Continue Reading
MemryX AI's MX3+ Chip: A Game Changer For AI Workloads

Updated Category News Views 80

A New Benchmark in AI Acceleration Out of Ann Arbor, MemryX AI has thrown its hat into the ring with the latest in AI hardware wizardry—the MX3+ chip. Now this beige wonder promises to rev things up in the world of AI, boasting a tenfold increase in peak AI compute and upping the memory stakes by the same factor. All while sipping power like a polite fly at a soda...

Continue Reading
OptiMantra's AI Scribe: Transforming Clinic Workflows

Updated Category News Views 6

Cutting Through the Noise: AI Scribe's Pragmatic Impact OptiMantra's fresh launch of AI Scribe isn't just another gadget on the shelf—it's gunning for the throat of that time-sucking monster called after-hours charting. You'd think clinic management would be about patients first, right? But turns out, the devil's in the details, with docs burning midnight oil drafting...

Continue Reading
Clarivate's IPOne Revolutionizes AI for IP Pros

Updated Category News Views 44

A New Dawn for IP Intelligence: Clarivate's Strategic Move Seems like Clarivate's out to shake things up in the IP world. Today, they've announced that their coveted patent and litigation intelligence is now seamlessly integrated with AI workflows on Claude through IPOne. For those not neck-deep in patents and trademarks every day, let’s break it down. This means IP...

Continue Reading
Ascletis Targets Obesity with New FDA Submission

Updated Category News Views 51

Breaking Ground with Innovative Obesity Treatment In the world of biotech, where breakthroughs are hard-fought and the stakes can seem insurmountable, Ascletis Pharma is swinging for the fences with their latest maneuver. They've submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC—a pioneering fixed-dose combo pill...

Continue Reading
Contract Workers Gain Traction in Workforce Planning

Updated Category News Views 14

Contract Workers: The New Normal Ever feel like we're on a merry-go-round when it comes to workforce planning? Well, buckle up folks, because contract workers are becoming the mainstay of staffing strategies. According to a recent survey, 71% of U.S. companies are not just dabbling, but fully integrating these workers into their plans. That's a seismic shift from just a...

Continue Reading
Goranson Bain Ausley Welcomes Marichalar: Family Law Focus

Updated Category News Views 20

Strengthening San Antonio's Family Law Field Brenda Marichalar is joining the ranks at Goranson Bain Ausley (GBA) with a reputation built on solid courtroom chops and a knack for making clients feel like they’re more than just case numbers. She’s landing right in San Antonio, a region that’s not just about the riverwalks and missions, but about real families...

Continue Reading

Top 5 Most Recently Viewed Articles

United Texas Bank's Move to National Charter: Game Changer

Updated Category News Views 8

A Bold Leap in the Banking Landscape Right out of the gate, United Texas Bank (UTB) isn't just taking another step forward; they're sprinting into a whole new world. We're talking about an epic leap from being a solid regional player to potentially shaking up the entire industry. With a nod from the Office of the Comptroller of the Currency (OCC), UTB is now stepping up...

Continue Reading
FibroBiologics Showcases Innovation at Major European Conference

Updated Category News Views 145

FibroBiologics to Share Innovations at Bio-Europe FibroBiologics, Inc. (Nasdaq: FBLG), a pioneering biotechnology company based in Houston, is leading the charge in developing groundbreaking therapies aimed at chronic diseases. Their innovative approach focuses on using fibroblast cells and derived materials to spearhead medical advancements in treatment strategies....

Continue Reading
EU Lawmaker Advocates Bitcoin As Legal Tender In Europe

Updated Category News Views 424

Bitcoin's Potential as Legal Tender in Europe In an exciting conversation around the future of finance, Sarah Knafo, a member of the European Parliament from France, voiced her strong belief that Bitcoin could be recognized as legal tender in Europe. Knafo pointed out that the ongoing inflationary policies in traditional fiat currencies create a fertile ground for Bitcoin...

Continue Reading
BMO Sheds U.S. Branches, Eyes Strategic Growth

Updated Category News Views 36

Why BMO is Slimming Down in the States You know, when a heavyweight like BMO Financial Group starts shedding branches left and right, you gotta ask yourself what the grand plan is. In a move that looks more like a strategic dance than an abrupt U-turn, BMO's gotten rid of 138 U.S. branches, handing them over to First-Citizens Bank. We're talking outlets scattered from...

Continue Reading
HVAC Sensors Market Surge: Forecast to Reach $7.88 Billion

Updated Category News Views 215

HVAC Sensors Market Overview Austin—The HVAC Sensors market is experiencing notable growth, fueled by the increasing demand for energy-efficient solutions and smart building technologies. According to industry reports, the market was valued at USD 4.57 billion in 2024 and is projected to surge to USD 7.88 billion by 2032, reflecting a robust CAGR of 7.06% during the...

Continue Reading